Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Review of Gender Differences in Medicine and Primary Factors Resulting in Gender Differences

의약품에서의 성별차이 및 유발요인

  • Kim, Hyun-Ju (Division of Life and Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University) ;
  • Choi, Jong-Min (Division of Life and Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University) ;
  • Kim, You-Jin (Division of Life and Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University) ;
  • Chae, Song-Wha (Division of Life and Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University) ;
  • Park, Jung-Hyun (Division of Life and Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University) ;
  • Oh, Ji-Hyun (Division of Life and Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University) ;
  • Kim, Kyung-Hee (Division of Life and Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University) ;
  • Heo, Jung-Sun (Division of Life and Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University) ;
  • Gwak, Hye-Sun (Division of Life and Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University) ;
  • Lee, Hwa-Jeong (Division of Life and Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University)
  • 김현주 (이화여자대학교 생명.약학부) ;
  • 최종민 (이화여자대학교 생명.약학부) ;
  • 김유진 (이화여자대학교 생명.약학부) ;
  • 채송화 (이화여자대학교 생명.약학부) ;
  • 박정현 (이화여자대학교 생명.약학부) ;
  • 오지현 (이화여자대학교 생명.약학부) ;
  • 김경희 (이화여자대학교 생명.약학부) ;
  • 허정선 (이화여자대학교 생명.약학부) ;
  • 곽혜선 (이화여자대학교 생명.약학부) ;
  • 이화정 (이화여자대학교 생명.약학부)
  • Received : 2010.06.26
  • Accepted : 2010.08.02
  • Published : 2010.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

This review summarizes gender differences in pharmacokinetics, pharmacodynamics, and adverse drug reactions. Gender differences in pharmacokinetics are categorized by four major factors: absorption/bioavailability, distribution, metabolism, and elimination. There are sex-based differences in gastric emptying time, gastric alcohol dehydrogenase activity, apparent volume of distribution, ${\alpha}1$-acid glycoprotein level, phase I (CYP) and phase II metabolizing enzymes, glomerular filtration rate, and drug transporters. This review also reports gender differences in pharmacokinetics and pharmacodynamics of cardiovascular agents, central nervous system acting agents and antiviral agents. In addition, it has been reported that females experience more adverse reactions such as coughing, tachycardia, nausea, vomiting, rash, hypersensitivity, hepatotoxicity, and metabolic disorder after taking cardiovascular, central nervous system acting and antiviral agents. Therefore, in order to provide optimal drug dosage regimens both in male and female, gender differences in pharmacokinetics, pharmacodynamics, and adverse drug reactions must be considered.

Keywords

References

  1. Protecting and Advancing Women's Health: The FDA Office of Women's Health Progress Report 10 years and Beyond., Mar. 2006. (http://www.fda.gov/womens/reports/report0306.pdf).
  2. Health Canada, Gender-based Analysis (http://www.hcsc.gc.ca/hl- vs/pubs/women-femmes/gender-sexes-eng.php)
  3. Health Canada's Gender-based Analysis Policy, Dec. 2000. (http://www.hc-sc.gc.ca/hl-vs/alt_formats/hpb-dgps/pdf/gbaeng.pdf).
  4. Mojaverian P, Rocci ML, Conner DP, et al., Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time. Clin Pharmacol Ther 1987; 41: 11-7. https://doi.org/10.1038/clpt.1987.3
  5. Frezza M, di Padova C, Pozzato G. High blood alcohol levels in women. The role of decreased gastric alcoholdehydrogenase activity and first-pass etabolism. N Engl J Med 1990; 322: 95-9. https://doi.org/10.1056/NEJM199001113220205
  6. Ochs HR, Greenblatt DJ, Divoll M, et al., Diazepam kinetics in relation to age and sex. Pharmacology 1981; 23: 24-30. https://doi.org/10.1159/000137524
  7. Greenblatt DJ, Allen MD, Harmatz JS, et al., Diazepam disposition determinants. Clin Pharmacol Ther 1980; 27: 301-12. https://doi.org/10.1038/clpt.1980.40
  8. Kristjansson F, Thorsteinsson SB. Disposition of alprazolam in human volunteers. Differences between genders. Acta Pharm Nord 1991; 3: 249-50.
  9. Wedel M, Pieters JE, Pikaar NA, et al., Application of a three-compartment model to a study of the effects of sex, alcohol dose and concentration, exercise and food consumption on the pharmacokinetics of ethanol in healthy volunteers. Alcohol 1991; 26: 329-36.
  10. Succari M, Foglietti MJ, Percheron F. Microheterogeneity of ${\alpha}1-acid$ glycoprotein: variation during the menstrual cycle in healthy women, and profile in women receiving estrogen-progestogen treatment. Clin Chim Acta 1990; 187: 235-41. https://doi.org/10.1016/0009-8981(90)90108-5
  11. Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein(a) levels: Effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arterioscler Thromb Vasc Biol 1997; 17: 1822-29. https://doi.org/10.1161/01.ATV.17.9.1822
  12. Brinkman-Van der Linden CM, Havenaar EC, et al., Oral estrogen treatment induces a decrease in expression of sialyl Lewis x on alpha 1-acid glycoprotein in females and male-to-female transsexuals. Arterioscler Thromb Vasc Biol 1996; 6: 407-12.
  13. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002; 72: 474-89. https://doi.org/10.1067/mcp.2002.128388
  14. Kahan BD, Kramer WG, Wideman C, et al., Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 1986; 41: 459-64. https://doi.org/10.1097/00007890-198604000-00009
  15. Austin KL, Mather LE, Philpot CR, et al., Intersubject and dose related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 1980; 10: 273-9. https://doi.org/10.1111/j.1365-2125.1980.tb01755.x
  16. Dilger K, Eckhardt K, Hofmann U, et al., Chronopharmacology of intravenous and oral modified release verapamil. Br J Clin Pharmacol 1999; 47: 413-9.
  17. Krecic-Shepard ME, Park K, Barnas C, et al., Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000; 68: 130-42. https://doi.org/10.1067/mcp.2000.108678
  18. Lemmens HJ, Burm AG, Hennis PJ, et al., Influence of age on the pharmacokinetics of alfentanil. Gender dependence. Clin Pharmacokinet 1990; 19: 416-22. https://doi.org/10.2165/00003088-199019050-00005
  19. Wenk M, Todesco L, Krahenbuhl S. Effect of St. John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, Nacetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004; 57: 495-9. https://doi.org/10.1111/j.1365-2125.2003.02049.x
  20. Lamba V, Lamba J, Yasuda K, et al., Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003; 307: 906-22. https://doi.org/10.1124/jpet.103.054866
  21. Gross JL, Friedman R, Azevedo MJ, et al., Effect of age and sex on glomerular filtration rate measured by 51Cr-EDTA. Braz J Med Biol Res 1992; 25: 129-34.
  22. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-11. https://doi.org/10.1056/NEJMoa021266
  23. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: Effect of age, gender, and body weight. Ther Drug Monit 1994; 16: 513-8. https://doi.org/10.1097/00007691-199410000-00013
  24. Frame BC, Facca BF, Nicolau DP, et al., Population pharmacokinetics of continuous infusion ceftazidime. Clin pharmacokinet 1999; 37: 343-50. https://doi.org/10.2165/00003088-199937040-00005
  25. Barbhaiya RH, Knupp CA, Pittman KA. Effects of age and gender on pharmacokinetics of cefepime.. Antimicrob Agents Chemother 1992; 36: 1181-5. https://doi.org/10.1128/AAC.36.6.1181
  26. Reigner BG, Welker HA. Factors influencing elimination and distribution of fleroxacin: meta analysis of individual data from 10 pharmacokinetic studies. Antimicrob Agents Chemother 1996; 40: 575-80.
  27. Wong LT, Sitar DS, Aoki FY. Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. Br J Clin Pharmacol 1995; 39: 81-4. https://doi.org/10.1111/j.1365-2125.1995.tb04414.x
  28. Gaudry SE, Sitar DS, Smyth DD, et al., Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clin Pharmacol Ther 1993; 54: 23-7. https://doi.org/10.1038/clpt.1993.104
  29. Legato M. Gender and the heart: sex-specific differences in normal anatomy and physiology. J Gend Specif Med 2000; 3: 15-8.
  30. Burke JH, Goldberger JJ, Ehlert FA, et al., Gender differences in heart rate before and after autonomic blockade: evidence against an intrinsic gender effect. Am J Med 1996; 100: 537-43. https://doi.org/10.1016/S0002-9343(96)00018-6
  31. Liu K, Ballew C, Jacobs DR Jr, et al., Ethnic differences in blood pressure, pulse rate, and related characteristics in young adults. The CARDIA study. Hypertension 1989; 14: 218-26. https://doi.org/10.1161/01.HYP.14.2.218
  32. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353-70.
  33. Villareal RP, Woodruff AL, Massumi A, et al., Gender and cardiac arrhythmias. Tex Heart Inst J 2001; 28: 265-75.
  34. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003; 42: 107-21. https://doi.org/10.2165/00003088-200342020-00001
  35. Hogstedt S, Lindberg B, Rane A, et al., Increased oral clearance of metoprolol in pregnancy. Eur J Clin Pharmacol 1983; 24: 217-20. https://doi.org/10.1007/BF00613820
  36. Llerena A, Cobaleda J, Martinez C, et al., Interethnic differences in drug metabolism: influence of genetic and environmental factors on desrisoquine hydroxylation phenotype. Eur J Drug Metabol Pharmacokinet 1996; 21: 129-38. https://doi.org/10.1007/BF03190261
  37. Wadelius M, Darj E, Frenne G, et al., Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997; 62: 400-7. https://doi.org/10.1016/S0009-9236(97)90118-1
  38. Kam KW, Qi JS, Chen M, et al., Estrogen reduces cardiac injury and expression of beta1-adrenoceptor upon ischemic insult in the rat heart. Pharmacol Exp Ther 2004; 309: 8-15. https://doi.org/10.1124/jpet.103.058339
  39. Thawornkaiwong A, Preawnim S, Wattanapermpool J, et al., Upregulation of b1-adrenergic receptors in ovariectomiz ed rat hearts. Life Sci 2003; 72: 1813-24. https://doi.org/10.1016/S0024-3205(02)02473-6
  40. Labbe' L, Sirois C, Pilote S, et al., Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000; 10: 425-38. https://doi.org/10.1097/00008571-200007000-00006
  41. Luzier AB, Killian A, Wilton JH, et al., Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999; 66: 594-601.
  42. Kendall MJ, Quarterman CP, Jack DB, et al., Metoprolol pharmacokinetics and the oral contraceptive pill. Br J Clin Pharmacol 1982; 14: 120-2. https://doi.org/10.1111/j.1365-2125.1982.tb04948.x
  43. Walle T, Walle K, Mathur RS, et al., Propranolol metabolism in normal subjects: association with steroid hormones. Clin Pharmacol Ther 1994; 56: 127-32. https://doi.org/10.1038/clpt.1994.115
  44. Gilmore DA, Gal J, Gerber JG, et al., Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther 1992; 261: 1181-6.
  45. Walle T, Byington RP, Furberg CD, et al., Biologic determinants of propranolol disposition: results from 1308 patients in the beta-Blocker Heart Attack Trial. Clin Pharmacol Ther 1985; 38: 509-18. https://doi.org/10.1038/clpt.1985.216
  46. Massana E, Barbanoj MJ, Moros C, et al., No sex-related pharmacokinetic and pharmacodynamic differences of captopril. Pharmacol Res 1997; 36: 41-7. https://doi.org/10.1006/phrs.1997.0202
  47. Pfeffer MA, Braunwald E, Moye LA, et al., Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-77. https://doi.org/10.1056/NEJM199209033271001
  48. Kimmelstiel C, Goldberg RJ. Congestive heart failure in women: focus on heart failure due to coronary artery disease and diabetes. Cardiology 1990; 77: 71-9.
  49. Vree TB, Dammers E, Ulc I, et al., Lack of male-female differences in disposition and esterase hydrolysis of ramipril to ramiprilat in healthy volunteers after a single oral dose. Scientific World J 2003; 3: 1332-43. https://doi.org/10.1100/tsw.2003.121
  50. Rathore SS, Curtis JP, Wang Y, et al., Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-8. https://doi.org/10.1001/jama.289.7.871
  51. Blaustein MP, Robinson SW, Gottlieb SS, et al., Sex, digitalis, and the sodium pump. Mol Interv 2003; 3: 68-2. https://doi.org/10.1124/mi.3.2.68
  52. Smith JB, Wade MB, Fineberg NS, et al., Influence of race, sex, and blood pressure on erythrocyte sodium transport in humans. Hypertension 1988; 12: 251-8. https://doi.org/10.1161/01.HYP.12.3.251
  53. Green HJ, Duscha BD, Sullivan MJ, et al., Normal skeletal muscle Na(þ)-K(þ) pump concentration in patients with chronic heart failure. Muscle Nerve 2001; 24: 69-6. https://doi.org/10.1002/1097-4598(200101)24:1<69::AID-MUS8>3.0.CO;2-O
  54. Rathore SS, Curtis JP, Wang Y, et al., Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-8. https://doi.org/10.1001/jama.289.7.871
  55. Rathore SS, Wang Y, Krumholz HM, et al., Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-11. https://doi.org/10.1056/NEJMoa021266
  56. Nicoline Jochmann, Karl Stangl, Edeltraut Garbe, et al., Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005; 26: 1585-95. https://doi.org/10.1093/eurheartj/ehi397
  57. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14: 73-86. https://doi.org/10.1038/sj.jhh.1000991
  58. Krecic-Shepard ME, Park K, Barnas C, et al., Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000; 68: 130-42. https://doi.org/10.1067/mcp.2000.108678
  59. Kloner RA, Sowers JR, DiBona GF, et al., for the Amlodipine Cardiovascular Community Trial Study Group. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 1996; 77: 713-22. https://doi.org/10.1016/S0002-9149(97)89205-3
  60. Isaacsohn J, Zinny M, Mazzu A, et al., Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults. Eur J Clin Pharmacol 2001; 56: 897-03. https://doi.org/10.1007/s002280000225
  61. Shepard DR, Jenid H, Thacker HL, et al., Gender, hyperlipidemia, and coronary artery disease. Compr Ther 2003; 29: 7-17. https://doi.org/10.1007/s12019-003-0002-y
  62. Avram MJ, Sanghvi R, Henthorn TK, et al., Determinants of Thiopental Induction Dose Requirements. Anesth Analg 1993; 76: 10-7.
  63. Vuyk J, Oostwouder C.J, Vletter A.A, et al., Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. Br J Anaesth 2001; 86: 183-8. https://doi.org/10.1093/bja/86.2.183
  64. Hoymork S.C, Raeder J, Grimsmo B, et al., Bispectral index, predicted and measured drug levels of targetcontrolled infusions of remifentanil and propofol during laparoscopic cholecystectomy and emergence. Acta Anaesthesiologica Scandinavica 2000; 44: 1138-44 https://doi.org/10.1034/j.1399-6576.2000.440918.x
  65. De Kock M, Scholtes J.L. Postoperative P.C.A. in abdominal surgery. Analysis of 200 consecutive patients. Acta anaesthesiologica Belgica 1991; 42: 85-91.
  66. Sarton E, Olofsen E, Romberg R, et al., Sex Differences in Morphine Analgesia : An Experimental Study in Healthy Volunteers. Anesthesiology 2000; 93: 1245-54. https://doi.org/10.1097/00000542-200011000-00018
  67. Burns J, Hodsman N, McLintock T, et al., The influence of patient characteristics on the requirements for postoperative analgesia. Anaesthesia 1989; 44: 2-6. https://doi.org/10.1111/j.1365-2044.1989.tb11086.x
  68. Sidebotham D, Dijkhuizen M.R, Schug S.A. The Safety and Utilization of Patient-Controlled Analgesia. J Pain Symptom Manage 1997; 14: 202-9. https://doi.org/10.1016/S0885-3924(97)00182-6
  69. Tsui SL, Tong W.N, Irwin M, et al., The efficacy, applicability and side-effects of postoperative intravenous patient-controlled morphine analgesia: an audit of 1233 Chinese patients. Anaesth Intensive Care 1996; 24: 658-64.
  70. Pleym H, Spigset O, Kharasch E.D, et al., Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiologica Scandinavica 2003; 47: 241-59. https://doi.org/10.1034/j.1399-6576.2003.00036.x
  71. Gourlay G.K, Kowalski S.R, Plummer J.L, et al., Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth Analg 1988; 67: 329-37.
  72. Gear R.W, Miaskowski C, Gordon N.C, et al., Kappaopioids produce significantly greater analgesia in women than in men. Nature Medicine 1996; 2: 1248-50. https://doi.org/10.1038/nm1196-1248
  73. Gear R.W, Gordon N.C, Heller P.H, et al., Gender difference in analgesic response to the kappa-opioid pentazocine. Neurosci Lett 1996; 205: 207-9. https://doi.org/10.1016/0304-3940(96)12402-2
  74. Gear R.W, Miaskowski C, Gordon N.C, et al., The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 1999; 83: 339-45. https://doi.org/10.1016/S0304-3959(99)00119-0
  75. Wing L.M, Miners J.O, Birkett D.J, et al., Lidocaine disposition-Sex differences and effects of cimetidine. Clin Pharmacol Ther 1984; 35: 695-701. https://doi.org/10.1038/clpt.1984.97
  76. Xue F.S, An G, Liao X, et al., The pharmacokinetics of vecuronium in male and female patients. Anesth Analg 1998; 86: 1322-7.
  77. Parker C.J, Hunter J.M, Snowdon S,L. Effect of age, gender and anaesthetic technique on the pharmacodynamics of atracurium. Br J Anaesth 1992; 69: 439-43. https://doi.org/10.1093/bja/69.5.439
  78. Xue F.S, Liao X, Liu J.H, et al., Dose-response curve and time-course of effect of vecuronium in male and female patients. Br J Anaesth 1998; 80: 720-4. https://doi.org/10.1093/bja/80.6.720
  79. Besch CL. Antiretroviral therapy in drug-naive patients infected with human immunodeficiency virus. Am J Med Sci 2004; 328: 3-9. https://doi.org/10.1097/00000441-200407000-00002
  80. Ofotokun I, Chuck SK, Hitti JE, et al., Antiretroviral pharmacokinetic profile: A review of sex differences. Gend Med 2007; 4(2): 106-19. https://doi.org/10.1016/S1550-8579(07)80025-8
  81. Rebecca Clark. Sex differences in antiretroviral therapyassociated intolerance and adverse events. Drug Saf 2005; 28: 1075-83. https://doi.org/10.2165/00002018-200528120-00003
  82. Floridia M, Giuliano M, Palmisano L, et al., Gender differences in the treatment of HIV infection. Pharmacol Res 2008; 58: 173-82. https://doi.org/10.1016/j.phrs.2008.07.007
  83. Anderson PL, Kakuda TN, Kawle S, et al., Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17: 2159-68. https://doi.org/10.1097/00002030-200310170-00003
  84. Stretcher BN, Pesce AJ, Frame PT, et al., Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1999; 38: 1541-7.
  85. de Maat MM, Huitema AD, Mulder JW, et al., Population pharmacokinetics of nevirapine in an unselected cohort of HIV-l-infected individuals. Br J Clin Pharmacol 2002; 54: 378-85. https://doi.org/10.1046/j.1365-2125.2002.01657.x
  86. Hitti J, Rosenkranz S, Cohn S, et al., For the adult AIDS Clinical Trial Group Study 398. Sex and weight as covariates in the pharmacokinetics of efavirenz, indinavir, and nelfinavir. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, Calif.
  87. Fletcher CV, Jiang H, Brundage RC, et al., Sex based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 3S9. lnfect Dis 2004; 189: 1176-84. https://doi.org/10.1086/382754
  88. Pai MP, Schriever CA, Diaz-Linares M, et al., Sex related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy 2004; 24: 592-9. https://doi.org/10.1592/phco.24.6.592.34744
  89. Trout H, Mentre F, Panhard X, et al., Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome. Antimicrob Agents Chemother 2004; 48: 538-45. https://doi.org/10.1128/AAC.48.2.538-545.2004
  90. Fuzeon [package insert]. Nutley, NJ: Roche Laboratories Inc. and Trimeris Inc; 2006. Available at: http://www,fuzeon.com/pdfs/fpi.pdf.
  91. Finkel DG, John G, Holland B, et al., Women have a greater immunological response to effective virological HIV-1 therapy. AIDS 2003; 17: 2009-11. https://doi.org/10.1097/00002030-200309050-00032
  92. Giordano TP, Wright JA, Hasan MQ, et al., Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis 2003; 37: 433-7. https://doi.org/10.1086/376638
  93. Moore AL, Mocroft A, Madge S, et al., Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. J Acquir Immune Defic Syndr 2001; 26: 159-63. https://doi.org/10.1097/00126334-200102010-00008
  94. Turner BJ, Laine C, Cosler L, et al., Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med 2003; 18: 248-57. https://doi.org/10.1046/j.1525-1497.2003.20122.x
  95. Murri R, Lepri AC, Phillips, et al., Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr 2003; 34: 184-90. https://doi.org/10.1097/00126334-200310010-00008
  96. Moore AL, Kirk O, Johnson AM, et al., Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32: 452-61. https://doi.org/10.1097/00126334-200304010-00017
  97. Lichenstien K, Delaney K, Ward D, et al., Clinical factors associated with incidence and prevalence of fat atrophy and accumulation. Antivir Ther 2000; 5: 61-2.
  98. Muurahainen N, Falutz J, Santos G, et al., Gender differences in lipodystrophy syndrome evaluated by SALSA. 3rd International Conference on Nutrition in HIV Infection. April 22-25, 1999; Cannes, France.
  99. Nguyen ML, Nagy GS, Hernandez I, et al., Use of HAART in women: similar response but greater toxicity. 14th International AIDS Conference; 2002 Jul; Barcelona
  100. Jacobson DL, Knox T, Gorbach S, et al., Evolution of fat atrophy (FA) and fat deposition (FD) over 1 year in a cohort of HIV infected men and women. Available from URL: http://www.retroconference.org/2002/ [Accessed 2004 Sep 24]
  101. Koko-Ekong S, Azubike U, Edong E, et al., Fat redistribution in HIV patients on non-protease (PI) Regimens-Study in 6 Centers in Nigeria. Available from URL: http://www. retroconference.org/2001/ [Accessed 2004 Sep 24]
  102. McDermott AY, Shevitz A, Knox T, et al., Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 2001; 74: 679-86.
  103. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Topics in HIV medicine : a publication of the International AIDS Society, USA. 2003; 11(2): 55-9.
  104. Moore RD, Fortgang I, Keruly J, et al., Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996; 101: 34-40. https://doi.org/10.1016/S0002-9343(96)00077-0
  105. Boxwell DE, Styrt BA. Lactic acidosis in patients receiving nucleoside reverse transcriptase inhibitors. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999; San Francisco (CA)
  106. Mazhude C, Jones S, Taylor C. Ethnic and gender differences in non-nucleoside reverse transcriptase inhibitor (NNRTI) induces rash. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; 2001 Jul 8-11; Buenos Aires
  107. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al., Sex difference in nevirapine rash. Clin Infect Dis 2001; 32: 124-9. https://doi.org/10.1086/317536
  108. Sanne I. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. AIDS 2000; 14[Suppl 4]: S12.
  109. Currier JS, Yetzer E, Potthoff A, et al., Gender differences in adverse events on ritonavir. An analysis from Abbott 247. 1st National Conference on Women and HIV. May 4-7, 1997; Pasadena, Calif.
  110. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222-39. https://doi.org/10.2165/00003495-199550020-00003
  111. Ofotokun I. Sex differences in the pharmacological effects of antiretroviral drugs: potential roles of drug transporters and Phase 1 and 2 metabolizing enzymes. Topics in HIV medicine : a publication of the International AIDS Society, USA. 2005, 12(2): 79-83.
  112. Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995; 275: 1011-8.
  113. Steiner H, Polliack A, Kimchi-Sarfaty C, et al., Differences in rhodamine- 123 efflux in B-type chronic lymphocytic leukemia suggest possible gender and stage variations in drug-resistance gene activity. Ann Hematol 1998; 76: 189-94. https://doi.org/10.1007/s002770050387
  114. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
  115. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35(5): 538-9. https://doi.org/10.1097/00126334-200404150-00014
  116. Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 2007; 21(18): 2455-64. https://doi.org/10.1097/QAD.0b013e3282f08cdc
  117. Nicastri E, Leone S, Angeletti C, et al., Sex issues in HIV- 1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother 2007; 60: 724-32. https://doi.org/10.1093/jac/dkm302